Interaksi Mitoksantron

When switching from drugs with prolonged immune effects, such as natalizumab, teriflunomide or mitoxantrone, the duration and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects when initiating GILENYA [see Warnings and Precautions (5.2)] . (label Fingolimod, Interaksi obat)

Coadministration of VOSEVI with BCRP substrates (e.g., methotrexate, mitoxantrone, imatinib, irinotecan, lapatinib, rosuvastatin, sulfasalazine, topotecan) is not recommended [see Clinical Pharmacology (12.3) ]. (label Sofosbuvir dan velpatasvir, Interaksi obat)

Cardiac Effects Because of the possible danger of cardiac effects in patients previously treated with daunorubicin or doxorubicin, the benefit-to-risk ratio of mitoxantrone injection therapy in such patients should be determined before starting therapy. (label Mitoksantron, Peringatan)

Cardiac Effects Because of the possible danger of cardiac effects in patients previously treated with daunorubicin or doxorubicin, the benefit-to-risk ratio of mitoxantrone injection therapy in such patients should be determined before starting therapy. (label Mitoksantron, Peringatan)

…(e.g., atorvastatin, bosentan, ezetimibe, fluvastatin, glyburide, olmesartan, pitavastatin, pravastatin, rosuvastatin, repaglinide, rifampin, simvastatin acid, SN-38 [active metabolite of irinotecan], valsartan) or breast cancer resistance protein (BCRP) (e.g., imatinib, irinotecan, lapatinib, methotrexate, mitoxantrone, rosuvastatin, sulfasalazine, topotecan). (label Eltrombopag, Interaksi obat)

Among 112 patients evaluable for safety on the mitoxantrone injection + hydrocortisone arm of the CALGB trial, 18 patients (19%) had a reduction in cardiac function, 5 patients (5%) had cardiac ischemia, and 2 patients (2%) experienced pulmonary edema. (label Mitoksantron, Peringatan)

For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while… (label Leflunomid, Interaksi obat)

When switching from drugs with prolonged immune effects, such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone, consider the duration and mode of action of these drugs because of additive immunosuppressive effects when initiating OCREVUS [see Warnings and Precautions (5.2) ]. (label Okrelizumab, Interaksi obat)

In a randomized comparative trial of mitoxantrone injection plus low-dose prednisone vs. low-dose prednisone, 7 of 128 patients (5.5 %) treated with mitoxantrone injection had a cardiac event defined as any decrease in LVEF below the normal range, congestive heart failure (n = 3), or myocardial ischemia. (label Mitoksantron, Peringatan)

Anthracycline Antibiotics High doses of cyclosporine (e.g., at starting intravenous dose of 16 mg/kg/day) may increase the exposure to anthracycline antibiotics (e.g., doxorubicin, mitoxantrone, daunorubicin) in cancer patients. (label Siklosporin, Interaksi obat)

For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while… (label Teriflunomid, Interaksi obat)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (label Mitoksantron, Interaksi obat)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (label Mitoksantron, Interaksi obat)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (label Mitoksantron, Interaksi obat)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (label Mitoksantron, Interaksi obat)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (label Mitoksantron, Interaksi obat)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (label Mitoksantron, Interaksi obat)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (label Mitoksantron, Interaksi obat)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (label Mitoksantron, Interaksi obat)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (label Mitoksantron, Interaksi obat)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (label Mitoksantron, Interaksi obat)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (label Mitoksantron, Interaksi obat)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (label Mitoksantron, Interaksi obat)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (label Mitoksantron, Interaksi obat)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (label Mitoksantron, Interaksi obat)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (label Mitoksantron, Interaksi obat)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (label Mitoksantron, Interaksi obat)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (label Mitoksantron, Interaksi obat)

• Prior treatment with an immunosuppressant (e.g., mitoxantrone, azathioprine, methotrexate, cyclophosphamide, mycophenolate mofetil). (label Natalizumab, Peringatan dan perhatian)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (label Mitoksantron, Interaksi obat)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (label Mitoksantron, Interaksi obat)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (label Mitoksantron, Interaksi obat)

In first-line comparative trials of mitoxantrone injection + cytarabine vs. daunorubicin + cytarabine in adult patients with previously untreated ANLL, therapy was associated with congestive heart failure in 6.5% of patients on each arm. (label Mitoksantron, Peringatan)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (label Mitoksantron, Interaksi obat)